ETFs & MarketsPremiumSAB Biotherapeutics Secures $95M Funding: Impact on Biotech ETF Liquidity
SAB Biotherapeutics has successfully raised $95 million, securing the necessary liquidity for operations through late 2027. This move highlights the resilience of institutional capital within the clinical-stage biotechnology sector.